Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Retained Earnings: 2019-2025

Historic Retained Earnings for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to -$1.3 billion.

  • Avidity Biosciences' Retained Earnings fell 69.52% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 69.52%. This contributed to the annual value of -$893.1 million for FY2024, which is 56.47% down from last year.
  • Latest data reveals that Avidity Biosciences reported Retained Earnings of -$1.3 billion as of Q3 2025, which was down 11.72% from -$1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Retained Earnings peaked at -$90.4 million during Q1 2021, and registered a low of -$1.3 billion during Q3 2025.
  • In the last 3 years, Avidity Biosciences' Retained Earnings had a median value of -$710.4 million in 2024 and averaged -$775.8 million.
  • Data for Avidity Biosciences' Retained Earnings shows a maximum YoY tumbled of 200.67% (in 2021) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Retained Earnings (Quarterly) stood at -$184.5 million in 2021, then plummeted by 94.28% to -$358.5 million in 2022, then slumped by 59.19% to -$570.8 million in 2023, then tumbled by 56.47% to -$893.1 million in 2024, then tumbled by 69.52% to -$1.3 billion in 2025.
  • Its Retained Earnings was -$1.3 billion in Q3 2025, compared to -$1.2 billion in Q2 2025 and -$1.0 billion in Q1 2025.